FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317862850> ?p ?o ?g. }

• W4317862850 endingPage "TPS782" @default.
• W4317862850 startingPage "TPS782" @default.
• W4317862850 abstract "TPS782 Background: GN is a first-line treatment option for patients (pts) with mPC. Poor prognosis and low 5-year survival rate ( < 5%) with mPC highlight the need for new therapeutics. Claudin 18.2 (CLDN18.2), a tight junction protein expressed exclusively on normal gastric epithelial cells, is maintained during malignant transformation in gastric cancers and is frequently expressed in some carcinomas from organs that do not normally express it, such as pancreatic cancer. Zolbetuximab, a chimeric IgG1 monoclonal antibody, binds to CLDN18.2 and mediates tumor cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This phase 2 study (NCT03816163) will assess safety and efficacy of GN alone or with zolbetuximab in CLDN18.2-positive mPC. Methods: The study was expanded to enroll approximately 369 pts with histologically confirmed mPC and high CLDN18.2 expression (moderate-to-strong IHC staining intensity in ≥75% of tumor cells). The study included a safety lead-in that enrolled 3-12 pts to assess safety/tolerability of zolbetuximab (n = 3 at 1,000 mg/m 2 on Cycle 1 Day 1 then 600 mg/m 2 Q2W, then expand/de-escalate using a 3+3 design) plus GN. Dose-limiting toxicities (DLTs, defined as a specified zolbetuximab-related toxicity that occurs during DLT assessment period) will be assessed after Cycle 1 (28 days). Based on the recommended phase 2 dose (RP2D), confirmed during the safety lead-in, approximately 357 pts will be randomized 2:1 to zolbetuximab Q2W on Days 1 and 15 plus GN on Days 1, 8, and 15 of each cycle (Arm 1), or GN alone on Days 1, 8, and 15 of each cycle (Arm 2). Randomization will be stratified by ECOG performance status (0 or 1) and liver metastasis (yes or no). At sites in Japan, DLTs (assessed from Cycle 1 Day 1 to Cycle 2 Day 1) will be evaluated in ≤6 pts randomized to the RP2D in Arm 1. Pts will undergo imaging (CT/MRI) at baseline and Q8W until investigator-assessed disease progression (RECIST v1.1) or the start of another systemic anticancer treatment, whichever comes earlier. In addition to confirming the RP2D during the safety lead-in, primary objectives are to assess whether treatment with zolbetuximab plus GN, versus GN alone, improves overall survival (randomization phase) and to establish the safety/tolerability profile of zolbetuximab plus GN (across the study). Secondary endpoints include progression-free survival, objective response rate, disease control rate, duration of response, pharmacokinetics, and health-related quality of life (per protocol amendment). Descriptive statistics will be used for continuous endpoints and frequency and percentage for categorical endpoints. Original protocol enrollment completion was in October 2021. Under the expanded protocol amendment, 95 of ~140 sites in North America, Latin America, Europe, and Asia Pacific were activated. Clinical trial information: NCT03816163 ." @default.
• W4317862850 created "2023-01-25" @default.
• W4317862850 creator A5006312789 @default.
• W4317862850 creator A5017079089 @default.
• W4317862850 creator A5033315908 @default.
• W4317862850 creator A5042673919 @default.
• W4317862850 creator A5048223620 @default.
• W4317862850 creator A5054430698 @default.
• W4317862850 creator A5054746174 @default.
• W4317862850 creator A5056197140 @default.
• W4317862850 creator A5059766169 @default.
• W4317862850 creator A5062064931 @default.
• W4317862850 creator A5075462213 @default.
• W4317862850 creator A5076438320 @default.
• W4317862850 date "2023-02-01" @default.
• W4317862850 modified "2023-10-17" @default.
• W4317862850 title "Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study." @default.
• W4317862850 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.tps782" @default.
• W4317862850 hasPublicationYear "2023" @default.
• W4317862850 type Work @default.
• W4317862850 citedByCount "1" @default.
• W4317862850 countsByYear W43178628502023 @default.
• W4317862850 crossrefType "journal-article" @default.
• W4317862850 hasAuthorship W4317862850A5006312789 @default.
• W4317862850 hasAuthorship W4317862850A5017079089 @default.
• W4317862850 hasAuthorship W4317862850A5033315908 @default.
• W4317862850 hasAuthorship W4317862850A5042673919 @default.
• W4317862850 hasAuthorship W4317862850A5048223620 @default.
• W4317862850 hasAuthorship W4317862850A5054430698 @default.
• W4317862850 hasAuthorship W4317862850A5054746174 @default.
• W4317862850 hasAuthorship W4317862850A5056197140 @default.
• W4317862850 hasAuthorship W4317862850A5059766169 @default.
• W4317862850 hasAuthorship W4317862850A5062064931 @default.
• W4317862850 hasAuthorship W4317862850A5075462213 @default.
• W4317862850 hasAuthorship W4317862850A5076438320 @default.
• W4317862850 hasConcept C121608353 @default.
• W4317862850 hasConcept C126322002 @default.
• W4317862850 hasConcept C143998085 @default.
• W4317862850 hasConcept C197934379 @default.
• W4317862850 hasConcept C2777292972 @default.
• W4317862850 hasConcept C2778375690 @default.
• W4317862850 hasConcept C2780210213 @default.
• W4317862850 hasConcept C2780258809 @default.
• W4317862850 hasConcept C71924100 @default.
• W4317862850 hasConcept C90924648 @default.
• W4317862850 hasConceptScore W4317862850C121608353 @default.
• W4317862850 hasConceptScore W4317862850C126322002 @default.
• W4317862850 hasConceptScore W4317862850C143998085 @default.
• W4317862850 hasConceptScore W4317862850C197934379 @default.
• W4317862850 hasConceptScore W4317862850C2777292972 @default.
• W4317862850 hasConceptScore W4317862850C2778375690 @default.
• W4317862850 hasConceptScore W4317862850C2780210213 @default.
• W4317862850 hasConceptScore W4317862850C2780258809 @default.
• W4317862850 hasConceptScore W4317862850C71924100 @default.
• W4317862850 hasConceptScore W4317862850C90924648 @default.
• W4317862850 hasIssue "4_suppl" @default.
• W4317862850 hasLocation W43178628501 @default.
• W4317862850 hasOpenAccess W4317862850 @default.
• W4317862850 hasPrimaryLocation W43178628501 @default.
• W4317862850 hasRelatedWork W2001578098 @default.
• W4317862850 hasRelatedWork W2006547351 @default.
• W4317862850 hasRelatedWork W2024463098 @default.
• W4317862850 hasRelatedWork W2037231105 @default.
• W4317862850 hasRelatedWork W2091019843 @default.
• W4317862850 hasRelatedWork W2111373770 @default.
• W4317862850 hasRelatedWork W2165480504 @default.
• W4317862850 hasRelatedWork W2168580276 @default.
• W4317862850 hasRelatedWork W2969118197 @default.
• W4317862850 hasRelatedWork W3042208798 @default.
• W4317862850 hasVolume "41" @default.
• W4317862850 isParatext "false" @default.
• W4317862850 isRetracted "false" @default.
• W4317862850 workType "article" @default.